Top Line Data for Jaguar Health's Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy ForthcomingAccesswire • 11/21/23
Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer SymposiumAccesswire • 11/09/23
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price RuleAccesswire • 11/08/23
Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate UpdatesAccesswire • 11/08/23
REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM ESTAccesswire • 11/07/23
Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East MarketsAccesswire • 11/02/23
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)Accesswire • 11/01/23
Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small PlanetAccesswire • 10/30/23
Napo Pharmaceuticals, a Jaguar Health Family Company, Accepted to Present Results of Its Pivotal Phase 3 OnTarget Study for Preventive Treatment of Cancer Therapy-Related Diarrhea December 7th at the San Antonio Breast Cancer SymposiumAccesswire • 10/25/23
Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health IndicationsAccesswire • 10/23/23
Independent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood DiseaseAccesswire • 10/19/23
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company's FDA-Approved Prescription DrugAccesswire • 10/18/23
Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor ForumAccesswire • 10/12/23
Jaguar Animal Health Exhibiting at October 12-14 VCS Annual Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in DogsAccesswire • 10/10/23
Jaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor ConferenceAccesswire • 09/28/23
Jaguar Health Launches TikTok and Instagram Contest to Raise Awareness About Common Yet Barely Addressed Health Condition: Surprise DiarrheaAccesswire • 09/27/23
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and SurvivorsAccesswire • 09/26/23
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHDAccesswire • 09/21/23
Filament Health's Magdalena Biosciences JV with Jaguar Health completes import of coca leaf from PeruProactive Investors • 09/20/23
Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment ConferenceAccesswire • 09/14/23
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)Accesswire • 09/13/23
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related DiarrheaAccesswire • 09/12/23
